Creo Medical Group (CREO)

Sector:

Health Care

Index:

FTSE AIM All-Share

 0.000p
   
  • Closing Price Chg:
      0.000p
  • 52 Week High: 20.00p
  • 52 Week Low: 10.00p
  • Currency: UK Pounds
  • Shares Issued: 412.47m
  • Volume: 0
  • Beta: 0.56

CREO Overview

Creo Medical was founded in 2003 as MicroOncology Ltd by Professor Chris Hancock, initially to target the treatment of cancers through use of high frequency microwave energy and dynamic matching techniques.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn -720.0% n/a
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue 11.3 n/a
Pr/Book 1.1  
Latest F'cast
Revenue n/a n/a
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

CREO Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-20 9.43 (23.46) (12.54)p n/a n/a n/a n/a 0.0%
31-Dec-21 25.16 (30.34) (14.48)p n/a n/a n/a n/a 0.0%
31-Dec-22 27.20 (30.90) (14.48)p n/a n/a n/a n/a 0.0%
31-Dec-23 4.00 (26.40) (8.00)p n/a n/a n/a n/a 0.0%
31-Dec-24 4.00 (29.00) (8.00)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

CREO Company Announcements

Award of Shares under Share Incentive Plan 14-Jan-2026 07:00 RNS
Notice of Capital Markets Day 27-Oct-2025 07:00 RNS
Capital Markets Day update 07-Oct-2025 11:37 RNS

CREO ShareCast News

Creo Medical's SpydrBlade Flex device receives U... 11-Jun-2025 ShareCast
Creo Medical eyes transition to full commerciali... 17-Feb-2025 ShareCast
Director dealings: Creo Medical chairman raises ... 16-Dec-2024 ShareCast

Latest CREO Director Deals

Traded Action Notifier PriceAmountValue
13-Jan-26 Transfer From Richard John Rees 0.000p 16,072 £0.00
13-Jan-26 Buy Richard John Rees 11.20p 8,036 £900.03
13-Jan-26 Transfer From Craig Jonathan Gulliford 0.000p 16,072 £0.00

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 3: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 4: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 5: Forecast figures based on normalised accounts.

 

CREO Market Data

Currency UK Pounds
Share Price 11.00p
Closing Price Change 0.000p
% Change 0.00 %
52 Week High 20.00p
52 Week Low 10.00p
Volume 0
Shares Issued 412.47m
Beta 0.56

CREO Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
5.70% above the market average5.70% above the market average5.70% above the market average5.70% above the market average5.70% above the market average
9.09% below the sector average9.09% below the sector average9.09% below the sector average9.09% below the sector average9.09% below the sector average
Price Trend
76.94% below the market average76.94% below the market average76.94% below the market average76.94% below the market average76.94% below the market average
31.43% below the sector average31.43% below the sector average31.43% below the sector average31.43% below the sector average31.43% below the sector average
Income Not Available
Growth
46.91% below the market average46.91% below the market average46.91% below the market average46.91% below the market average46.91% below the market average
65.71% below the sector average65.71% below the sector average65.71% below the sector average65.71% below the sector average65.71% below the sector average

CREO Dividends

No dividends found

Trades for --2026

Time Volume / Share Price
0 @ 0.000p

CREO Key Personnel

CEO Craig Jonathan Gulliford
CFO Richard John Rees
Chair Kevin Crofton

Top of Page